Saltar al contenido
Merck

Immunomodulatory effect of diethylcarbamazine citrate plus filarial excretory-secretory product on rat hepatocarcinogenesis.

International immunopharmacology (2014-12-17)
Mahmoud Abdel-Latif, Thabet Sakran, Gamal El-Shahawi, Hoda El-Fayoumi, Al-Mahy El-Mallah
RESUMEN

Diethylcarbamazine citrate (DEC) had a significance in anti-filarial chemotherapy, while excretory-secretory product (ES) is released from adult filarial females. The target of the current study was to examine the immunomodulatory effect of DEC, Setaria equina ES or a combination of them on rat hepatocellular carcinoma (HCC) induced by diethylnitrosamine (DEN). In vitro effect of combined DEC and ES or ES alone on lipopolysaccharide (LPS)-stimulated rat peripheral blood mononuclear cells (PBMCs) was tested through IFN-γ assay in culture supernatants. In addition, single or repeated doses of DEC, ES or DEC+ES have been applied in white albino rats to test the effect on HCC. Levels of IFN-γ and anti-ES IgG antibodies in rat serum were assayed using ELISA. Hemolytic complement activity (CH50) was determined in serum while the concentration of nitric oxide (NO) was assayed in liver tissue. The infiltration of NK cells as well as the expression of MHC Iproliferating cell nuclear antigen (PCNA), inducible NO synthase (iNOS), Bcl2 and p53 were determined using immunohistochemistry. There was a dose-dependent increase in IFN-γ after in vitro exposure to DEC+ES. Repeated ES doses increased NO concentration (p<0.05) and expression of iNOS but reduced CH50 (p<0.001), while repeated DEC+ES doses could increase anti-ES IgG (p<0.01), IFN-γ level (p<0.05) and NK cell infiltration. The same treatments could also reduce the expression of MHC I expression, PCNA, Bcl2 and p53. This study has shown immunomodulatory and protective effects of DEC+ES repeated doses on rat HCC.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Peróxido de hidrógeno solution, contains inhibitor, 30 wt. % in H2O, ACS reagent
Sigma-Aldrich
Peróxido de hidrógeno solution, 30 % (w/w) in H2O, contains stabilizer
Sigma-Aldrich
Peróxido de hidrógeno solution, 50 wt. % in H2O, stabilized
Sigma-Aldrich
Peróxido de hidrógeno solution, 30% (w/w), puriss. p.a., reag. ISO, reag. Ph. Eur.
Sigma-Aldrich
o-Phenylenediamine, flaked, 99.5%
Sigma-Aldrich
Peróxido de hidrógeno solution, contains ~200 ppm acetanilide as stabilizer, 3 wt. % in H2O
Sigma-Aldrich
Peróxido de hidrógeno solution, contains inhibitor, 35 wt. % in H2O
Sigma-Aldrich
Peróxido de hidrógeno solution, purum p.a., ≥35% (RT)
Millipore
Peróxido de hidrógeno solution, 3%, suitable for microbiology
Sigma-Aldrich
o-Phenylenediamine, Peroxidase substrate, ≥98.0%, powder
Supelco
Peróxido de hidrógeno solution, ≥30%, for trace analysis
Sigma-Aldrich
Peróxido de hidrógeno solution, contains inhibitor, 30 wt. % in H2O, meets USP testing specifications
Sigma-Aldrich
Peróxido de hidrógeno solution, SAJ first grade, ≥30.0%
Sigma-Aldrich
Peróxido de hidrógeno solution, 34.5-36.5%
Sigma-Aldrich
Barbital
Supelco
Peróxido de hidrógeno solution, 30 % (w/w), for ultratrace analysis
Sigma-Aldrich
o-Phenylenediamine, tablet, 20 mg substrate per tablet
Sigma-Aldrich
o-Phenylenediamine, sublimed, ≥99%
Sigma-Aldrich
Barbital, BioXtra, ≥99.0% (T)
Sigma-Aldrich
Peróxido de hidrógeno solution, tested according to Ph. Eur.
Sigma-Aldrich
Peróxido de hidrógeno solution, contains potassium stannate as inhibitor, 30-32 wt. % in water, semiconductor grade, 99.999% trace metals basis
Barbital, European Pharmacopoeia (EP) Reference Standard